TY  - JOUR
T1  - COst-effectiveness of screening strategies for identifying pediatric diabetes mellitus and dysglycemia
AU  - Wu E, Kazzi NG, Lee JM
Y1  - 2013/01/01
N1  - 10.1001/jamapediatrics.2013.419
JO  - JAMA Pediatrics
SP  - 32
EP  - 39
VL  - 167
IS  - 1
N2  - Objective 
                  To conduct a cost-effectiveness analysis of screening strategies for identifying children with type 2 diabetes mellitus and dysglycemia (prediabetes/diabetes).Design 
                  Cost simulation study.Setting 
                  A one-time US screening program.Study Participants 
                  A total of 2.5 million children aged 10 to 17 years.Intervention 
                  Screening strategies for identifying diabetes and dysglycemia.Main Outcome Measures 
                  Effectiveness (proportion of cases identified), total costs (direct and indirect), and efficiency (cost per case identified) of each screening strategy based on test performance data from a pediatric cohort and cost data from Medicare and the US Bureau of Labor Statistics.Results 
                  In the base-case model, 500 and 400 000 US adolescents had diabetes and dysglycemia, respectively. For diabetes, the cost per case was extremely high ($312 000-$831 000 per case identified) because of the low prevalence of disease. For dysglycemia, the cost per case was in a more reasonable range. For dysglycemia, preferred strategies were the 2-hour oral glucose tolerance test (100% effectiveness; $390 per case), 1-hour glucose challenge test (63% effectiveness; $571), random glucose test (55% effectiveness; $498), or a hemoglobin A1c threshold of 5.5% (45% effectiveness; $763). Hemoglobin A1c thresholds of 5.7% and 6.5% were the least effective and least efficient (ranges, 7%-32% and $938-$3370) of all strategies evaluated. Sensitivity analyses for diabetes revealed that disease prevalence was a major driver of cost-effectiveness. Sensitivity analyses for dysglycemia did not lead to appreciable changes in overall rankings among tests.Conclusions 
                  For diabetes, the cost per case is extremely high because of the low prevalence of the disease in the pediatric population. Screening for diabetes could become more cost-effective if dysglycemia is explicitly considered as a screening outcome.
SN  - 2168-6203
M3  - doi: 10.1001/jamapediatrics.2013.419
UR  - http://dx.doi.org/10.1001/jamapediatrics.2013.419
ER  -